Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More? Available to Purchase

Acquired mutations in BTK, PLCG2, and BCL2 are associated with resistance to continuous targeted agent therapy in chronic lymphocytic leukemia (CLL). Here, we discuss new evidence that limiting the duration of CLL therapy may prevent the evolution of such resistance mutations, potentially facilitating effective retreatment strategies.

See related article by Jain et al., p. 498